Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases

a technology of fractalkine and adenovirus, which is applied in the direction of chemokines, peptides/protein ingredients, peptides, etc., can solve the problems of muscle rigidity, motor system, motor coordination and speed impairment, etc., to prevent and/or reduce the loss of synuclein nigral neurons, and the effect of treating or ameliorating neuroinflammatory and neurodegenerative diseases

Inactive Publication Date: 2021-05-06
UNIV OF SOUTH FLORIDA +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text is about using a specific type of receptor called CX3CR1 to treat diseases that affect the brain, such as Parkinson's disease. The text explains that by activating this receptor, it can protect and reduce the loss of nerve cells in the brain. This provides a potential therapeutic strategy for preventing and treating neurological diseases.

Problems solved by technology

Major symptoms of PD include disturbance of the motor system, in which motor coordination and speed become impaired, muscles become rigid, and uncontrollable twitching of groups of muscles produces tremor.
However, microglial neurotoxicity can occur after excessive and uncontrolled stimulation or when microglia function is impaired.
Specifically, CX3CR1− / − mice exhibited an increased classical activation state with higher levels of IL-1β and TNFα, which resulted in increased neurotoxicity.
While a complete loss of FKN signaling can lead to microglia-mediated neuronal injury and death, it is unclear whether supraphysiological levels of FKN would be neuroprotective.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases
  • Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases
  • Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases

Examples

Experimental program
Comparison scheme
Effect test

example 1

ective Effects of AAV-Mediated Transfer of Fractalkine

[0115]This Example shows that increased FKN expression in the brain region via rAAV-based gene therapy has neuroprotective effects. To examine the therapeutic effects of FKN, FKN is over-expressed using rAAV and cell-specific promoters. Adeno-associated viruses have been used as vectors for gene therapy. rAAV serves as an excellent vector for gene delivery into the CNS. rAAV is non-pathogenic and has low immunogenicity. In addition, all viral genes can be removed from recombinant AAV virus, and long-term expression is attainable.

[0116]Three forms of mouse FKN constructs are made and amplified by PCR: 1) the native form (SEQ ID NO:6) (nFKN, which can form both soluble and membrane-bound forms after subsequent processing), 2) the soluble domain of FKN (sFKN) (SEQ ID NO:7), and 3) a protease resistant mutant membrane-bound form (mFKN) (SEQ ID NO:8). To facilitate in vivo detection, hemaggluttinin (HA) tags are attached to the FKN co...

example 2

ion of Neuronal Cells Using Recombinant AAV9-FKN Vectors

[0122]Both the soluble form and the membrane-bound mutant rAAV9-FKN are produced using a murine version of the CX3CL1 gene driven by the hybrid chicken β-actin cytomegalovirus promoter and are tagged with hemagglutinin (HA) peptide sequence for ease of detection. Prior to virus production, the rAAV vector is tested in HEK293 cells to evaluate sFKN and mFKN proteins are produced from the expression cassette. Cell lysate and conditioned media from transfected cells are examined using Western blot analysis to determine sFKN and mFKN expression. An anti-HA tag Western blot analysis of transfected HEK 293 cells reveals that sFKN is secreted into the media, while mFKN remains only in the cell lysate fraction (FIG. 1a).

[0123]The synthetic FKN proteins are biologically active. Briefly, conditioned media from HEK 293 cells transfected with the sFKN plasmid are used to confer bioactivity by measuring the amount of secreted TNF-α from BV2...

example 3

of MPTP-Induced Impairment of Motor Coordination by the Soluble Isoform of FKN

[0125]The effects of rAAV-sFKN and rAAV-mFKN on MPTP-induced motor deficits are examined using an accelerating rotarod. FKN− / − Sham mice display no motor coordination impairment when compared to WT-Sham (FIG. 7). Five days after the last MPTP injection, all MPTP-treated groups display a significant trend for performance impairment (F (1, 145)=42.11, p<0.001), as measured by average latency to fall across three trials compared to WT-Sham mice (FIG. 7). Treatment with sFKN significantly improves MPTP-induced behavioral deficits when compared to mFKN (p=0.002) and GFP (p<0.001) viral control.

[0126]Following rotarod performance assessment, mice are sacrificed and striatal tissues are dissected for biochemical analysis. Consistent with each group's rotarod performance, Western blot analysis reveals a significant loss of striatal tyrosine hydroxylase (TH) as a result of MPTP administration (p<0.001), ranging fro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The subject invention pertains to the use of fractalkine (FKN, CX3CL1) and its receptor CX3CR1 for treatment of neuroinflammation and / or neurodegeneration. In one embodiment, the present invention provides a method for treatment of neuroinflammation and / or neurodegenerative diseases, comprising: administering, to cells of a subject in need of such treatment, an adeno-associated virus that comprises a functional fractalkine gene operably linked to transcriptional control elements. In one embodiment, the subject invention is used to treat or ameliorate Parkinson's disease. The present invention can also be used to treat or ameliorate neuroinflammatory and / or neurodegenerative diseases including, but not limited to, Alzheimer's disease, epilepsy, aging, and traumatic brain injury.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This application claims the benefit of U.S. provisional application Ser. No. 61 / 503,958, filed Jul. 1, 2011, which is herein incorporated by reference in its entirety.BACKGROUND OF THE INVENTION[0002]Parkinson's disease (PD) is a disabling, progressive neurodegenerative disorder. Major symptoms of PD include disturbance of the motor system, in which motor coordination and speed become impaired, muscles become rigid, and uncontrollable twitching of groups of muscles produces tremor. The symptoms of PD are primarily caused by a progressive loss of dopaminergic neurons within the pars compacta of the substantia nigra (SNpc). The degeneration of dopaminergic neurons decreases the levels of the neurotransmitter dopamine in the nigrostriatal system.[0003]Neuroinflammation may also play a role in the degeneration of nigrostriatal pathway and the progression of PD pathology. For example, changes in synaptic transmission, axonal transport and incre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K14/52C07K14/715
CPCC07K14/521A61K38/00C07K14/7158A61K48/00C12N2750/14143C12N2750/14171
Inventor GEMMA, CARMELINABICKFORD, PAULA C.NASH, KEVIN R.MORGANTI, JOSHBACHSTETTER, ADAM
Owner UNIV OF SOUTH FLORIDA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com